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CORONARY ARTERY DISEASE 
1. Stable ischemic heart disease Coronary 
Revascularization vs. Medical Therapy Alone:  
A SCAI Statement
An international group of investigators performed a rig-
orous meta-analysis of 25 randomized clinical trials (RCTs) 
with an enrolment of 19,806 patients conducted between 1979 
and 2020 that compared the effects of medical therapies alone 
with medical therapies plus revascularization in patients with 
stable ischemic heart disease (SIHD). Strict entry criteria 
were established to assure the analysis was restricted to stud-
ies involving elective, deferrable treatments of patient with 
SIHD. The analysis found that use of revascularization with 
percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting surgery (CABG) was linked to a statistically 
important 21% reduction in late cardiovascular death. Fur-
thermore, the magnitude of benefit appeared to increase over 
time. In fact, meta-regression techniques indicated that prior 
studies might have missed this finding principally due to short 
follow up. The research team performed multiple sensitivity 
analyses to determine how certain conditions influenced the 
results of the meta-analysis such as treatment in the context 
of a recent acute coronary syndrome, inclusion of patients 
requiring treatment of chronic total occlusions, or studies in 
which >30% of patients received CABG. Also, a few studies 
were judged to have a meaningful risk of bias. Exclusion of 
these studies did not alter the significance of the cardiovascular 
mortality risk reduction with an initial invasive strategy. The 
meta-analysis also found that an initial invasive approach was 
associated with a 24% reduction in spontaneous MI, which had 
a larger impact on survival than peri-procedural MI. In fact, 
the meta-analysis found that peri-procedural MI in the RCTs 
did not impact reported cardiac death rates. Furthermore, the 
meta-analysis linked a survival advantage to lower spontane-
ous MI rates especially among patients with extensive disease. 
An especially important observation from this report evolved 
from a meta-regression analysis which found that longer fol-
low up was associated with increased observed benefit with an 
invasive strategy, and that differences in conclusions between 
RCTs could be explained largely by differences in follow up 
duration. While total MI rates may not appear to be different 
between treatment strategies in the short run, revascularization 
helps over a long timeline by more effectively lowering the risk 
of spontaneous MI; this observation may be overwhelmed by 
the effects of peri-procedural MI associated with undergoing 
revascularization if follow up is relatively short. Therefore, this 
meta-analysis indicates that coronary revascularization with 
PCI or CABG provides a long-term cardiovascular survival 
advantage over an initial conservative approach in patients with 
stable ischemic heart disease by lowering rates of spontane-
ous MI, providing a biologically plausible explanation for the 
observed benefit. Eliano Navarese, Euro-PCR, May 2021.
2. PCI vs. CABG in 3VD or UPLMD: 10-Year 
All-Cause Death According to Completeness of 
Revascularization in Patients with Three-Vessel Disease 
or Left Main Coronary Artery Disease: Insights from 
the SYNTAX Extended Survival Study
Ten-year all-cause death according to incomplete (IR) 
versus complete revascularization (CR) has not been fully 
investigated in patients with three-vessel disease (3VD) and/
or left main coronary artery disease (LMCAD) undergoing 
percutaneous coronary intervention (PCI) vs. coronary artery 
bypass grafting (CABG). The SYNTAX Extended Survival 
Study evaluated vital status up to 10 years in patients who 
were originally enrolled in the SYNTAX trial. In the present 
sub-study, outcomes of the CABG CR group were compared 
with the CABG IR, PCI CR, and PCI IR groups. In addition, 
in the PCI cohort, the residual SYNTAX score (rSS) was used 
to quantify the extent of IR and to assess its association with 
fatal late outcome. The rSS of 0 suggests CR, whereas a rSS 
>0 identifies degree of IR. IR was more frequently observed 
in patients with PCI vs. CABG (56.6% vs. 36.8%) and more 
common in those with 3VD than LMCAD in both PCI (58.5% 
vs. 53.8%) and CABG arm (42.8% vs. 27.5%). Patients un-
dergoing PCI with CR had no significant difference in 10-year 
all-cause death compared with those undergoing CABG (22.2% 
for PCI with CR vs. 24.3% for CABG with IR vs. 23.8% for 
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CABG with CR). In contrast, those with PCI and IR had a 
significantly higher risk of all-cause death at 10 years com-
pared with CABG and CR (33.5% vs. 23.7%; adjusted hazard 
ratio [aHR]: 1.48; 95% confidence interval [CI]: 1.15–1.91). 
When patients with PCI were stratified according to the rSS, 
those with a rSS ≤8 had no significant difference in all-cause 
death at 10 years as the other terciles (22.2% for rSS=0 vs. 
23.9% for rSS >0–4 vs. 28.9% for rSS >4–8), whereas a rSS 
>8 had a significantly higher risk of 10-year all-cause death 
as compared with those undergoing PCI with CR (50.1% vs. 
22.2%; aHR: 3.40; 95% CI: 2.13–5.43). IR is common after 
PCI, and the degree of incompleteness was associated with 
10-year mortality. If it is unlikely that complete (or nearly 
complete; rSS <8) revascularization can be achieved with PCI 
in patients with 3VD, CABG should be considered. Kuniaki 
Takahashi, et al. Circulation. 2021 12;394(10206):1325–1334. 
021 May 20. doi: 10.1161/CIRCULATIONAHA.120.046289.
3. Ultrathin Strut Biodegradable Polymer Sirolimus-
Eluting Stent versus Durable Polymer Everolimus-
Eluting Stent for Patients With Acute ST-Segment 
Elevation Myocardial Infarction Undergoing Primary 
Percutaneous Coronary Intervention. Data from 
BIOSTEMI trial
Two-year results from the BIOSTEMI trial, which were 
presented during a late-breaking trial session at the 2021 Car-
diovascular Research Technologies meeting. In BIOSTEMI 
the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting 
Stent compared with durable Polymer Everolimus-Eluting 
Stent in patients with STEMI undergoing Primary Percutane-
ous Coronary Intervention. It was an investigator-initiated, 
multicenter, assessor-blind, randomized superiority trial using 
Bayesian methods. Patients with STEMI undergoing primary 
PCI within 24 h of symptom onset were randomized in a 1:1 
ratio to receive BP-SES (n=649) or DP-EES (n=651). The 
primary endpoint was: target lesion failure (TLF), a composite 
of cardiac death, target vessel myocardial re-infarction, and 
clinically indicated target lesion revascularization (TLR), at 
2 years. Between April 2016 and March 2018, 1,300 patients 
were included. Baseline characteristics were comparable 
between the 2 treatment groups. Follow-up through 2 years 
was complete in 1,221 patients (94%). At 2 years, TLF oc-
curred in 33 patients (5.1%) treated with BP-SES and in 53 
patients (8.1%) treated with DP-EES (rate ratio: 0.58; 95% 
Bayesian credible interval: 0.40 to 0.84; posterior probability 
of superiority = 0.998). The difference was driven by a lower 
incidence of clinically indicated TLR in patients treated with 
BP-SES compared with DP-EES (2.5% vs. 5.1%; rate ratio: 
0.52; 95% Bayesian credible interval: 0.30 to 0.87; posterior 
probability of superiority = 0.993). There were no significant 
differences in rates of cardiac death, target vessel myocardial 
re-infarction, and definite stent thrombosis between the 2 
treatment arms. Therefore, in patients with STEMI undergoing 
primary PCI, BP-SESs were superior to DP-EESs with respect 
to TLF at 2 years. The difference was driven by lower rates of 
ischemia-driven TLR. David Kandzari, 2021 Cardiovascular 
Research Technologies meeting.
4. Acute myocardial infarction and cardiogenic shock. 
Outcomes of mechanical circulatory support for acute 
myocardial infarction complicated by cardiogenic shock
The objective of this retrospective cohort study was 
to describe trends and outcomes of Impella usage in acute 
myocardial infarction complicated by cardiogenic shock 
(AMICS) treated with MCS (Impella or IABP) using real-
world observational data from the National Inpatient Sample 
(NIS). The study included 54,480 hospitalizations (10.5%, 
utilizing Impella) for AMICS managed with MCS, between 
January 2012 and December 2017. Throughout the study 
period, Impella usage increased yearly to 19.9% of AMICS 
cases in 2017. After propensity score matching, Impella was 
associated with higher in-hospital mortality (odds ratio [OR] 
1.74, 95% confidence interval [CI] 1.41–2.13) and transfu-
sions (OR 1.97, 95% CI 1.40–2.78) than IABP, without 
association with acute kidney injury or stroke. Impella use 
was associated with higher hospital costs (mean difference 
$22,416.80 [95% CI $17,029–27,804]). Impella usage for 
AMICS increased significantly from 2012 to 2017 and was 
associated with increased in-hospital mortality and costs. In 
addition, Impella has been associated with higher in-hospital 
mortality than intra-aortic balloon pump (IABP) in the Pre-
mier Healthcare Database and National Cardiovascular Data 
Registry. Therefore, further data are needed to support the 
use of MCS in acute MI combined with cardiogenic shock. 
Yeunjung Kim et al. Cath. Cardiov. Intervention, 2021 ahead 
of print. doi.org/10.1002/ccd.29834.
STRUCTURAL HEART DISEASE 
1. Global epidemiology of valvular heart disease
This is an interesting review article discussing the global 
burden of Valvular heart disease (VHD), the geographical 
variation in the presentation and clinical management, and 
finally the temporal trends in the disease burden. VHD is a 
major contributor to loss of physical function, quality of life 
and longevity. The epidemiology of VHD varies substantially 
around the world, with a predominance of functional and 
degenerative disease in high-income countries, and a predomi-
nance of rheumatic heart disease in low-income and middle-
income countries. Reflecting this distribution, rheumatic 
heart disease remains by far the most common manifestation 
of VHD worldwide and affects approximately 41 million 
people. By contrast, the prevalence of calcific aortic stenosis 
and degenerative mitral valve disease is 9 and 24 million 
people, respectively. Despite a reduction in global mortality 
related to rheumatic heart disease since 1900, the death rate 
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has remained fairly static since 2000. Meanwhile, deaths from 
calcific aortic stenosis have continued to rise in the past 20 
years. Epidemiological data on other important acquired and 
congenital forms of VHD are limited. An ageing population 
and advances in therapies make an examination of the changing 
global epidemiology of VHD crucial for advances in clinical 
practice and formulation of health policy. The most important 
key points highlighted are: 
 - The prevalence of VHD is growing worldwide as a con-
sequence of improved survival and the ageing population. 
 - Rheumatic heart disease (RHD) remains the most prevalent 
form of VHD and contributes to substantial premature 
mortality and reduced quality of life; RHD is primarily 
encountered in middle-income and low-income countries 
and specific (usually indigenous) groups in high-income 
countries. Calcific aortic valve disease is highly age-related, 
and its prevalence is increasing rapidly in high-income 
countries. 
 - Endocarditis is increasing in incidence and prevalence 
as a consequence of improved diagnosis and an ageing, 
susceptible population undergoing an increasing range and 
complexity of medical interventions. 
 - Valve abnormalities are a frequent component of congenital 
heart disease; bicuspid aortic valve is most commonly 
encountered, and its prevalence seems to be uniform 
across the world. 
 - Epidemiological information on patients who have under-
gone surgical or transcatheter valve intervention is limited, 
but this population is growing exponentially (especially 
in high-income countries); forecasting trends is difficult 
owing to the rapid evolution of these interventions and 
of therapies that might reduce the need for interventional 
treatment. Coffey S, et al. Nat Rev Cardiol. 2021, ahead 
of print. doi: 10.1038/s41569-021-00570-z.
2. Impact of Surgical and Transcatheter Aortic Valve 
Replacement in Low-Gradient Aortic Stenosis: a meta-
analysis
Severe aortic stenosis (AS) associated with a low (LG) 
transaortic gradient (AVA <1cm2, mean gradient <40mmHg) 
seen in up to one-third of patients put forward for TAVI. LG 
severe AS encompasses a wide variety of pathophysiology, 
including classical low-flow, LG (LF-LG), paradoxical LF-
LG, and normal-flow, LG (NF-LG) AS. An uncertainty exists 
regarding the impact of AVR on each subclass of LG AS. 
PubMed and Embase were queried through October 2020 to 
identify studies comparing survival with different management 
strategies (SAVR, TAVR, and conservative) in patients with 
LG AS. Pairwise meta-analysis comparing AVR versus con-
servative management and network meta-analysis comparing 
SAVR versus TAVR versus conservative management were 
performed. The aim of this study was to assess the impact 
of aortic valve replacement (AVR) on survival in patients 
with each subclass of low-gradient (LG) aortic stenosis (AS) 
and to compare outcomes following surgical AVR (SAVR) 
and transcatheter AVR (TAVR). 32 studies with a total of 
6,515 patients and a median follow-up time of 24.2 months 
(interquartile range: 36.5 months) were included. AVR was 
associated with a significant decrease in all-cause mortality 
in classical LF-LG (hazard ratio [HR]: 0.42; 95% confidence 
interval [CI]: 0.36 to 0.48), paradoxical LF-LG (HR: 0.41; 
95% CI: 0.29 to 0.57), and NF-LG (HR: 0.41; 95% CI: 0.27 
to 0.62) AS compared with conservative management. SAVR 
and TAVR were each associated with a decrease in all-cause 
mortality in classical LF-LG (HR: 0.46 [95% CI: 0.38 to 0.55] 
and 0.49 [95% CI: 0.37 to 0.64], respectively), paradoxical 
LF-LG (HR: 0.42 [95% CI: 0.28 to 0.65] and 0.42 [95% CI: 
0.25 to 0.72], respectively), and NF-LG (HR: 0.40 [95% CI: 
0.21 to 0.77] and 0.46 [95% CI: 0.26 to 0.84], respectively) 
AS compared with conservative management. No significant 
difference was observed between SAVR and TAVR. In all 
subclasses of LG AS, AVR was associated with a signifi-
cant decrease in all-cause mortality regardless of surgical or 
transcatheter approach. Ueyama H, et al. JACC Cardiovasc 
Interv. 2021 Apr 28;S1936-8798(21)00813-X. doi: 10.1016/j.
jcin.2021.04.038.
3. TAVI and low surgical risk patients: 8-year outcomes 
for patients with aortic valve stenosis at low surgical 
risk randomized to transcatheter vs. surgical aortic 
valve replacement. Data from the Notion Trial
In the NOTION trial, patients with symptomatic severe 
aortic valve stenosis were randomized to TAVI or SAVR. Clini-
cal status, echocardiography, structural valve deterioration, 
and failure were assessed using standardized definitions. In 
total, 280 patients were randomized to TAVI (n=145) or SAVR 
(n=135). Baseline characteristics were similar, including mean 
age of 79.1±4.8 years and a mean STS score of 3.0±1.7%. 
At 8-year follow-up, the estimated risk of the composite 
outcome of all-cause mortality, stroke, or myocardial infarc-
tion was 54.5% after TAVI and 54.8% after SAVR (P=0.94). 
The estimated risks for all-cause mortality (51.8% vs. 52.6%; 
P=0.90), stroke (8.3% vs. 9.1%; P=0.90), or myocardial in-
farction (6.2% vs. 3.8%; P=0.33) were similar after TAVI and 
SAVR. The risk of structural valve deterioration was lower 
after TAVI than after SAVR (13.9% vs. 28.3%; P=0.0017), 
whereas the risk of bioprosthetic valve failure was similar 
(8.7% vs. 10.5%; P=0.61). Therefore, in patients with severe 
aortic valve stenosis at low surgical risk randomized to TAVI 
or SAVR, there were no significant differences in the risk for 
all-cause mortality, stroke, or myocardial infarction, as well as 
the risk of bioprosthetic valve failure after 8 years of follow-up. 
Troels Højsgaard Jørgensen, et al. European Heart Journal 
(2021) 00, 1–8. doi:10.1093/eurheartj/ehab375.
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4. Mitral Surgery After Transcatheter Edge-to-Edge 
Repair: Society of Thoracic Surgeons Database Analysis
As the number of Transcatheter edge-to-edge (TEER) mitral 
repair progressively increase passing to younger patients often 
may complicated by residual or recurrent mitral regurgitation. 
Therefore, an increasing need for surgical re-intervention has 
been reported, but operative outcomes are not well defined. 
The Society of Thoracic Surgeons (STS) Adult Cardiac Sur-
gery Database was used to identify 524 adults who underwent 
mitral surgery after TEER between July 2014 and June 2020. 
Emergencies (5.0%; n=26), previous mitral surgery (5.3%; 
n=28), or open implantation of transcatheter prostheses (1.5%; 
n=8) were excluded. The primary outcome was 30-day or 
in-hospital mortality. In the study cohort of 463 patients, the 
median age was 76 years (interquartile range [IQR]: 67 to 
81 years), median left ventricular ejection fraction was 57% 
(IQR: 48% to 62%), and 177 (38.2%) patients had degenerative 
disease. Major concomitant cardiac surgery was performed in 
137 (29.4%) patients: in patients undergoing isolated mitral 
surgery, the median STS-predicted mortality was 6.5% (IQR: 
3.9% to 10.5%), the observed mortality was 10.2% (n=23 
of 225), and the ratio of observed to expected mortality was 
1.2 (95% confidence interval [CI]: 0.8 to 1.9). Predictors of 
mortality included urgent surgery (odds ratio [OR]: 2.4; 95% 
CI: 1.3 to 4.6), non-degenerative/unknown etiology (OR: 2.2; 
95% CI: 1.1 to 4.5), creatinine of >2.0 mg/dl (OR: 3.8; 95% 
CI: 1.9 to 7.9) and age of >80 years (OR: 2.1; 95% CI: 1.1 to 
4.4). In a volume outcomes analysis in an expanded cohort of 
591 patients at 227 hospitals, operative mortality was 2.6% 
(n=2 of 76) in 4 centers that performed >10 cases versus 12.4% 
(n=64 of 515) in centers performing fewer (p=0.01). The sur-
gical repair rate after failed TEER was 4.8% (n=22) and was 
6.8% (n=12) in degenerative disease. In conclusion, this study 
indicates that mitral repair is infrequently achieved after failed 
TEER, which may have implications for treatment choice in 
lower-risk and younger patients with degenerative disease. 
These findings should inform patient consent for TEER, clini-
cal trial design, and clinical performance measures. Joanna 
Chikwe, et al. J Am Coll Cardiol. 2021 Jul 6;78(1):1–9. doi: 
10. Mitral regurgitation and MITRA-FR vs. COAPT:1016/j.
jacc.2021.04.062. Epub 2021 May 1.
5. Incidence and clinical relevance of persistent 
iatrogenic atrial septal defect after percutaneous mitral 
valve repair
Percutaneous mitral valve repair (PMVR) requires trans-
septal puncture resulting in iatrogenic atrial septal defect 
(iASD). The impact of persistent iASD was previously in-
vestigated. However, data were diverse and inconclusive. 53 
patients who underwent MITRACLIP were retrospectively 
included. Based on the presence of iASD in transesophageal 
echocardiography (TEE) after 6 months, patients were divided 
in two groups (iASD group vs. non-iASD group). Impact of 
iASD on outcome at 6 months and at two years was evaluated. 
Persistent iASD was detected in 62% of patients. Independent 
predictors for persistent iASD were female gender and reduced 
left ventricular ejection fraction. At 6-month follow-up, there 
was no difference in reduction of NYHA class (ΔNYHA = 
1.3±1 in iASD group vs. 0.9±1 in non-iASD group, p=0.171). 
There was a significant difference in right ventricular end 
diastolic diameter (RVEDd) (42±8 mm in iASD-group vs. 
39±4 mm in non-iASD group, p=0.047). However, right 
ventricular systolic function (TAPSE) (14±7 mm in iASD 
group vs. 16±8 mm in non-iASD group, p=0.176) and right 
ventricular systolic pressure (RVSP) (40±12 mmHg in iASD 
group vs. 35±10 mmHg in non-iASD group, p=0.136) were 
still comparable between both groups. At 2 years follow-up, 
there was no significant difference regarding rate of rehospi-
talization (24% vs 15%, p=0.425) or mortality (12% vs 10%, 
p=0.941) between both groups. Incidence of persistent iASD 
after MITRACLIP is markedly high. Despite the increase in 
right ventricular diameter in patients with persistent iASD, 
these patients were not clinically compromised compared to 
patients without persistent iASD. Mhd Nawar Alachkar, et 
al. Sci Rep. 2021 Jun 16;11(1):12700. doi: 10.1038/s41598-
021-92255-3.
6. European position paper on the management 
of patients with patent foramen ovale. Part 
II - Decompression sickness, migraine, arterial 
deoxygenation syndromes and select high-risk clinical 
conditions
Patent foramen ovale (PFO) is implicated in the pathogen-
esis of a number of medical conditions. However, the high 
prevalence of a PFO in the normal population (20-30%) implies 
that PFO can often be an incidental finding rather than a causa-
tive one. To help clinicians with decision making, the European 
Association of Percutaneous Cardiovascular Interventions 
(EAPCI) Scientific Documents and Initiatives Committee 
invited eight European scientific societies and international 
experts to develop interdisciplinary position statements on 
the management of PFO, based on systematic assessments of 
the literature. A previous position paper has been published 
addressing issues related to cryptogenic thromboembolism. 
The present interdisciplinary paper reports the approach to 
patients with PFO and decompression sickness, desaturation 
syndromes, migraine, and other clinical presentations. We 
present the most important key points: 
 - Decompression sickness (DCS): A PFO can allow para-
doxical embolization of venous gaseous emboli (VGE) 
when there is a rise in right heart pressures due to pul-
monary gas embolism or physical exercise; however, in 
large PFOs with spontaneous right-to-left (R-T-L) shunts, 
paradoxical VGE can also occur without other provoca-
38
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tion. No evidence-based statements can be formulated 
regarding PFO closure as primary prevention of DCS. 
In professional divers, primary screening for PFO can be 
foreseen in accurately selected cases with high-risk work 
activity, in order to evaluate the possibility of a primary 
percutaneous closure. Primary screening for PFO could be 
carried out in select military pilots performing intensive 
very high-altitude flight activities. However, primary PFO 
closure in pilots should be weighed against the possibil-
ity of disqualification from flight activity. When a PFO 
is an incidental finding in pilots or divers with no history 
of DCS, no restriction in conventional altitude flights is 
required, while recreational divers should be counselled 
by an experienced diving physician.
 - Migraine: Factors that may suggest a pathogenic role of 
PFO in migraine are the presence of: 1) an aura and 2) 
previous stroke. Older age and small shunts through the 
PFO would suggest a less likely causative relationship 
between a PFO and migraine.
 - Pregnancy: In asymptomatic women planning a pregnancy 
or during a normal pregnancy, PFO should not be systemati-
cally screened. In women with a known PFO but otherwise 
without coagulation diseases, no primary prevention for 
thrombotic systemic embolism should be foreseen.
 - Neurosurgery: All patients scheduled for neurosurgery 
in the sitting position should routinely undergo screening 
for a PFO prior to surgery. Christian Pristipino et al. Eur 
Heart J. 2021 Apr 21;42(16):1545-1553. doi: 10.1093/
eurheartj/ehaa1070.
7. Transcatheter strategies for tricuspid valve disease
The tricuspid valve (TV), which is commonly referred to 
as the ‘‘forgotten valve’’ has received increasing attention in 
recent years. Anatomical challenges include the large annulus, 
paucity of valve/annular calcification, adjacency of the right 
coronary artery, and fragility of the valve tissue. Current ap-
proaches under investigation in feasibility and early phase 
clinical trials include edge-to-edge repair, coaptation enhance-
ment, annuloplasty, heterotopic caval valve implantation, 
and percutaneous tricuspid valve replacement. Transcatheter 
therapies for TVD continue to gain momentum, as evidenced 
by three studies presented at EuroPCR 2021: TRISCEND, 
TriBAND, and CLASP TR. On the whole, the early data 
suggest these devices are a viable treatment for tricuspid 
regurgitation (TR), investigators told the meeting’s virtual 
audience, yet they also speak to the diverse approaches—an-
nular reduction, transcatheter edge-to-edge repair (TEER), and 
valve replacement—aimed at addressing this clinical niche. 
Although recent studies have suggested potential advantages 
of transcatheter intervention compared with medical therapy, 
major questions that need to be addressed by future trials in-
clude whether earlier intervention for tricuspid regurgitation 
may be beneficial, and whether combined mitral and tricuspid 
procedures improve procedural success and clinical outcomes. 
We present the most recent data: 
 - The TRISCEND study and Evoque device: Evoque is 
a self-expanding from nitinol valve engages the leaflets, 
chords, and annulus to achieve secure placement. It is 
“designed to be delivered from a transfemoral approach 
over a stiff wire placed in the RV apex. The TRISCEND 
study enrolled 56 patients, 84% of whom were NYHA 
functional class III-IV and 92% had at least severe TR. 
In 68% the etiology of TR was functional, whereas 11% 
had degenerative TR and the rest had mixed/other origins. 
Nearly half (43%) had undergone a prior valve surgery or 
intervention. By 30-day follow-up all patients had a reduc-
tion of at least one TR grade and 95% had a decrease of two 
or more grades. Three-quarters were NYHA class I-II. There 
were significant improvements in 6-minute walk distance 
and Kansas City Cardiomyopathy Questionnaire (KCCQ) 
score. At 30-day follow-up, one patient (1.9%) had died 
of a cardiovascular cause. There were no strokes or MIs. 
Severe bleeding, the most-common complication, was 
seen in 22.6%, while 3.8% required nonelective tricuspid 
valve reintervention and one 1.9% had major access-site/
vascular complications. Two patients died in total, for an 
all-cause mortality rate of 3.8%. Based on the results of this 
study, a pivotal trial evaluating this therapy—TRISCEND 
II—has been initiated. A possible limitation could be the 
potential of bioprosthesis degeneration and durability. 
Susheel Kodali. EuroPCR 2021.
 - The CLASP TR study and Pascal device: Pascal device 
is similar to mitra clip leading to edge-to-edge repair of the 
valve. The study presented the latest results from CLASP 
TR for TEER with the Pascal device, showed that much 
like at 30 days, 6-month results in these challenging cases 
of tricuspid valve disease are encouraging. Pascal device 
received CE Mark approval for TR last year in Europe. 
Seventy percent of the 63 patients had started out with 
NYHA class III-IV at baseline. Six months later, 84% were 
NYHA class I-II. At baseline, TR was categorized in 69% 
as “massive or torrential”, a proportion that dropped to 8% 
by 6 months. Within 6 months, 89% improved by at least 
one TR grade and 70% saw at least a two-grade reduction 
in TR. There were significant gains in quality life on the 
KCCQ. At 6-month follow-up, two patients each (2.3%) 
had died of CV causes or experienced stroke, and there 
were no MIs. Severe bleeding occurred in five patients 
(7.9%), while reintervention related to the device and major 
access-site/vascular complications requiring intervention 
were seen in one patient (1.6%) each. Other events included 
all-cause death (3.2%), heart failure hospitalization (6.3%), 
and single-leaflet device attachment assessed by a core 
lab (4.8%). Based on the above mentioned data in USA 
the CLASP-II TR pivotal trial is underway. However one 
can mention as a limitation the possibility of an incom-
CARdIOLOgy CORNER
39
plete solution, because usually the disease makes the gap 
very large in the tricuspid setting and usually you cannot 
eliminate TR completely and therefore there is high risk 
for recurrence. Mackram Eleid. Euro-PCR 2021.
 - The TriBAND study and Cardioband device: This 
device is designed to reduce annular dilation, allowing 
better leaflet coaptation, “which is the key pathology of 
functional tricuspid regurgitation. Cardioband —origi-
nally developed for mitral regurgitation— was the first 
device, in 2018, to receive CE Mark approval for the 
tricuspid indication. In this single-arm, multicenter study 
the safety and effectiveness of the Cardioband tricuspid 
valve reconstruction system was evaluated. TriBAND 
study included 61 patients with severe and symptomatic 
functional TR who hadn’t responded to diuretic therapy. 
Most (85%) were NYHA class III-IV at baseline. By dis-
charge, 59% had reached moderate-or-lower-grade TR, 
with 78% showing a reduction of at least one grade. Sep-
tolateral annular diameter decreased by 20% pointing out 
that these changes were “accompanied by early evidence 
of right heart remodeling.” At 30-day follow-up, there 
was one MI (1.6%) but no CV mortality or stroke. There 
was one all-cause death. The most common complications 
were severe bleeding, in seven patients (11.5%); major 
access-site/vascular complications and coronary artery 
injury requiring intervention, each seen in four patients 
(6.6%); and new need for renal replacement therapy, in 
two patients (3.3%). The majority (74%) were now in 
NYHA class I-II, and overall KCCQ score had improved 
by 17 points. Results showed significant reductions in 
annular diameter and TR severity, accompanied by early 
evidence of right heart remodeling and improvements in 
functional status and quality of life and by addressing the 
annulus and maintaining the native tricuspid leaflets, the 
Cardioband tricuspid system preserves the option for future 
interventions such as leaflet repair or valve replacement. 
Georg Nickenig et al. Euro Intervention 2021; Epub ahead 
of print. DOI: 10.4244/EIJ-D-21-00300.
ARTERIAL HYPERTENSION
Blood Pressure Levels in Young Adulthood and Midlife 
Stroke Incidence in a Diverse Cohort
We examined the longitudinal association between blood 
pressure (BP) and stroke incidence in young and middle-aged 
adults. BP measured during 9 examinations of the CARDIA 
study (Coronary Artery Risk Development in Young Adults) 
from 1985–1986 to 2015–2016 was used to classify participants 
(n=5079) according to the 2017 Hypertension Clinical Practice 
Guidelines. We used the highest BP obtained through the third 
examination (1990–1991) to define baseline BP categories; 
time-dependent categories (accounting for change in BP over 
time) were determined incorporating follow-up measurements. 
BP groups at ages 30 and 40 years were also defined. Stroke 
events were adjudicated until 2018. Mean age at baseline was 
29.8 years. Stroke occurred in 100 participants. Stroke inci-
dence was higher (P<0.001) in Black versus White participants. 
After adjustment with Cox models for sociodemographic and 
cardiovascular risk factors, stage 2 hypertension was associ-
ated with a higher risk of stroke at baseline (hazard ratio, 3.72 
[95% CI, 2.12–6.54]), as a time-dependent variable (hazard 
ratio, 5.84 [95% CI, 3.43–9.95]), at age 30 (hazard ratio, 4.14 
[95% CI, 2.19–7.82]) and at age 40 (hazard ratio, 5.59 [95% 
CI, 3.35–9.31]), compared with normal BP. Elevated BP and 
stage 1 hypertension showed more modest increases in risk. 
As a continuous variable, systolic BP ≥90 mmHg at age 40 
was directly associated with stroke risk. These findings call 
for primordial prevention strategies to reduce population BP 
levels among young and middle-aged adults, particularly in 
Black young adults given ≈4-fold higher stroke incidence, 
including within values traditionally considered to be normal. 
Yarin Gerber, et al. Hypertension 2021 5;77(5):1683-1693. 
doi: 10.1161/HYPERTENSIONAHA.120.16535.
HEART FAILURE
Update on Heart Failure: Revised universal definition 
and classification of heart failure, 2021
In 2019 the ESC has published new guidelines on heart 
failure (HF). Recently, the members of the Heart Failure Society 
of America, Heart Failure Association of the European Society 
of Cardiology, Japanese Heart Failure Society, Writing Com-
mittee of the Universal Definition of Heart Failure, endorsed by 
the Canadian Heart Failure Society, Heart Failure Association 
of India, Cardiac Society of Australia and New Zealand, and 
Chinese Heart Failure Association and with the participation 
from total 14 different countries and 6 continents written this 
expert consensus report regarding the definitions of HF. The 
majority of the HF care is provided by non-cardiologists, 
including general practitioners, internal medicine or family 
medicine clinicians, hospitalists, emergency room providers, 
and other specialists, therefore, this report provides a uni-
versal definition of HF that is clinically relevant, simple but 
conceptually comprehensive, with the ability to sub-classify 
and to encompass stages within, with universal applicability 
globally, and with prognostic and therapeutic validity and ac-
ceptable sensitivity and specificity. This document proposes:
 - A universal definition of HF as a clinical syndrome with 
symptoms and/or signs caused by a structural and/or func-
tional cardiac abnormality and corroborated by elevated 
natriuretic peptide levels and/or objective evidence of 
pulmonary or systemic congestion. 
 - Α revised stages of HF as: At risk for HF (Stage A), for 
patients at risk for HF but without current or prior symp-
toms or signs of HF and without structural or biomarker 
evidence of heart disease. Pre-heart failure (Stage B), for 
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patients without current or prior symptoms or signs of 
HF but evidence of structural heart disease or abnormal 
cardiac function, or elevated natriuretic peptide levels. 
HF (Stage C), for patients with current or prior symptoms 
and/or signs of HF caused by a structural and/or functional 
cardiac abnormality. Advanced HF (Stage D), for patients 
with severe symptoms and/or signs of HF at rest, recurrent 
hospitalizations despite guideline-directed medical therapy 
(GDMT), refractory or intolerant to GDMT, requiring 
advanced therapies such as consideration for transplant, 
mechanical circulatory support, or palliative care.
 - A new and revised classification of HF according to left 
ventricular ejection fraction (LVEF), including: HF with 
reduced ejection fraction (HFrEF): symptomatic HF with 
LVEF ≤40%; HF with mildly reduced ejection fraction 
(HFmrEF): symptomatic HF with LVEF 41–49%; HF 
with preserved ejection fraction (HFpEF): symptomatic 
HF with LVEF ≥50%; and HF with improved ejection frac-
tion (HFimpEF): symptomatic HF with a baseline LVEF 
≤40%, a ≥10 point increase from baseline LVEF, and a 
second measurement of LVEF >40%. Biykem Bozkurt, et 
al. European Journal of Heart Failure 2021; 23:352–380, 
doi:10.1002/ejhf.2115.
ΑRRYTHMIAS 
2021, European Heart Rhythm Association (EHRA) 
Practical Guide on the Use of Non-Vitamin K 
Antagonist Oral Anticoagulants in Patients with Atrial 
Fibrillation
This Practical Guide is an update of the 2018 version 
provided by the collaboration of members of EHRA, Heads of 
the National Cardiac Societies, and medical experts from the 
manufacturers of the NOACs and intends to provide support 
for safe and effective use of NOACs in every daily clinical 
practice. Although NOACs have demonstrated an improved 
efficacy/safety ratio, there are practical aspects to the proper 
use of the individual NOACs in many clinical situations. In 
addition, there are aspects of NOACs which are not well-
researched, but may be relevant in clinical practice. Finally, 
the use of NOACs in daily clinical practice does not require 
monitoring of coagulation since all four phase-III RCTs com-
paring NOACs to VKAs have been conducted without dose 
adjustments based on plasma level measurements. However, 
assessment of the anticoagulant effect of NOACs may be de-
sirable in certain, rare situations. Most routine coagulometers 
are capable of measuring NOAC plasma levels within ≤30min. 
Institutions should strongly consider 24/7 availability of these 
tests for emergency situations. We describe the use of NOACs 
in various clinical scenarios:
 - In patients with Mechanical Valves: NOACS are con-
traindicated since they have been excluded form pivotal 
RCTs. 
 - After bioprosthetic valve implantation or valve repair: 
Traditionally, VKA have been the anticoagulants of choice 
during the first 1–3 months post-surgery in patients with 
AF. NOACs appear as a valid option after this period 
(given data from the pivotal phase III studies as well as 
the dedicated RIVER trial). Results of the latter imply 
that patients may be treated with a NOAC even earlier 
after biological valve replacement however more solid 
data are needed.
 - Post transcatheter aortic valve implantation (TAVI): For 
TAVI patients, who have an indication for anticoagulation 
(e.g. AF), a small RCT of 157 patients comparing OAC 
alone with a combination of OAC + clopidogrel, indicated 
a benefit from OAC alone in terms of reduced bleeding 
without compromising ischemic events. It is important to 
remember that OAC (including NOAC) monotherapy may 
be considered after TAVI in patients with AF.
 - Patients with AF and HCM: Patients with HCM may be 
eligible for NOAC therapy.
 - Patients with AF after coronary artery bypass grafting 
(CABG): In patients with concomitant AF, the combination 
of a single antiplatelet agent (aspiring or clopidogrel) with 
a NOAC appears reasonable but —in contrast to patients 
after percutaneous coronary intervention (PCI)/acute 
coronary syndrome (ACS)— randomized trial data are 
lacking. The combination of DAPT with a NOAC seems 
undesirable due to its inherent bleeding risk, but again, no 
prospective evidence is available.
 - After percutaneous coronary intervention (PCI)/acute 
coronary syndrome (ACS): According to the current ESC 
guidelines for AF as well as for NSTEMI/ACS, a short 
course of triple therapy is recommended for up to 1 week 
in all patients with AF undergoing PCI. Therefore, a low 
threshold for prolonging triple therapy with DAPT and 
NOAC up to 30 days may be advisable in patients with 
a high thrombotic risk. In contrast, continuation of triple 
therapy beyond 30 days rarely seems warranted.
 - In patients with a recent ACS (<1 year) who develops 
new-onset AF: ACS guidelines recommended DAPT for 
up to 1 year after the acute event in patients without indi-
cation for OAC, and high-risk patients might require an 
even longer DAPT duration. In patients with a recent acute 
coronary syndrome (<1 year) who develops new-onset 
AF NOAC should be started and the need for continuing 
DAPT should be carefully weighed against the increased 
bleeding risk. Beyond 1 month after the event, aspirin can 
be stopped in the majority of such patients. 
 - In patients with chronic coronary syndrome or acute 
coronary syndrome >1 year) who develops atrial fibril-
lation: Patients with a CCS developing AF should receive 
anticoagulation, depending on their CHA2DS2-VASc score 
(which per definition will be ≥1). A NOAC without any 
antiplatelet agent appears to be the preferred strategy for 
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these patients, based on the results of the four landmark 
NOAC trials and the ‘Atrial Fibrillation and Ischemic 
Events with Rivaroxaban in Patients with Stable Coronary 
Artery Disease’ (AFIRE) trial. An additional antiplatelet 
agent should only be considered in individual patients with 
a very high ischemic- and low bleeding risk. 
 - In patients with atrial fibrillation who develop left 
ventricular (LV) thrombus after myocardial infarction: 
In the absence of randomized studies, it remains uncer-
tain whether a NOAC is effective in the treatment of LV 
thrombi complicating a large infarction. One observational 
study suggests that NOACs were associated with a higher 
incidence of thromboembolic events compared to VKA in 
(mostly non-AF) patients with a LV thrombus, while others 
showed a similar rate of thrombus resolution. Although 
residual confounding can never be excluded in these set-
tings, VKA should be viewed as standard of care for the 
treatment of patients with LV thrombus until more data. 
If a thrombus persists during follow-up despite confirmed 
good adherence to the NOAC regimen an individual-
ized management strategy is required. This may include 
switching to a different type of NOAC (direct thrombin 
inhibitor to FXa-inhibitor or vice versa) or INR-tailored 
VKA-therapy.
 - Old patients with AF: This group of patients have more 
favorable outcomes on OAC than without, and on NOACs 
than on VKA.
 - Frail patients with AF: Frailty and pre-frail states are com-
mon with advancing age and raise specific considerations 
regarding the risk-benefit of OAC. Frailty is associated with 
weight loss and a risk for deterioration in renal function. 
As a result, patients need to be weighed and their renal 
function monitored regularly to ensure safe NOAC dosing. 
There may be no benefit to OAC in states of severe frailty 
or where life expectancy is likely to be limited. 
 - Patients with AF and risk for falling: Falling per se is not 
a contraindication to NOAC use but precautions should be 
taken and modifiable bleeding risk factors assessed includ-
ing, importantly, co-use of antiplatelet agents.
 - Patients with AF and low Body weight (BW): Low BW 
(BMI <18.5 kg/m2) may increase the exposure to NOACs 
increasing the risk of bleeding. Moreover, renal function 
may be overestimated in underweight patients due to their 
reduced muscle mass, BW ≤60 kg requires dose reduction 
of apixaban [in patients with age ≥80 years and/or serum 
Creatinine ≥1.5 mg/dl] as well as for edoxaban, whereas it 
is in itself not a factor for dose reduction of rivaroxaban or 
use of lower dose dabigatran. Both apixaban and edoxaban 
showed consistent efficacy and safety compared to warfarin 
in underweight patients when compared with the overall 
study population. Drug concentrations and inhibition of 
Factor Xa did not differ in patients with low BW (range 
30–55 kg) from patients with middle body weight in an 
analysis from ENGAGE AF-TIMI 48. As such, both drugs 
may be a preferred choice for patients ≤60 kg. If therapy 
with a NOAC is warranted in low and very low weight 
individuals, measurement of trough levels may be consid-
ered to check for accumulation of the drug. However, no 
evidence-based recommendations can be given regarding 
dose reduction in cases where trough levels are above the 
expected range.
 - Black, Hispanic, or other ethnicities patients with AF - 
Black patients have been shown to have a lower incidence 
of AF but appear to be at higher risk of stroke. The rate 
of stroke in AF equally appears higher and outcomes may 
be worse in Hispanics vs. non-Hispanic patients. NOACs 
should also be the preferred therapy for Black or Hispanic 
patients, particularly due to the oftentimes difficult and 
suboptimal alternative of VKA therapy. 
 - Patients in pregnancy: NOACs are contraindicated.
 - Pediatric patients. Pediatric patients have been excluded 
from the pivotal stroke prevention RCTs and AF with need 
for OAC is rare in this population. NOAC therapy should 
be discouraged in children but can be considered in fully 
grown adolescents with body weight >50 kg.
 - Patients with AF in thrombocytopenia - There is no 
‘safe’ cut-off above which NOAC therapy is without 
risk in patients with thrombocytopenia. In addition to the 
absolute number of platelets the dynamics of the platelet 
count, the underlying reason for thrombocytopenia, and 
special risk factors (including the likelihood of dysfunc-
tional platelets as well as other coagulation abnormalities) 
need to be considered. As a general advice – PLT <20.000/
μl -> Avoid NOAC therapy, PLT >50.000/μl. -> proceed 
with caution and close monitoring, PLT >20.000/μl and 
<50.000/μl. -> proceed with very caution, close monitor-
ing and half dose Given the lack of a large evidence base 
for guidance the decision for NOAC treatment needs to 
follow an individualized, team-based approach including 
the patient and his/her needs and expectations (shared 
decision-making). 
 - NOACs and heparin-induced thrombocytopenia (HIT): 
Thrombocytopenia is an uncommon side effect of NOACs, 
but isolated cases have been reported. In HIT ± thrombosis 
(HIT/HITT) there is growing evidence that NOACs are not 
recognized by pre-existing HIT antibodies, do not complex 
with platelet factor 4 and do not cause platelet aggregation. 
NOAC therapy may hence constitute a viable less expensive 
and easier to administer alternative to parenteral heparin 
substitutes (e.g. argatroban, fondaparinux) especially if the 
latter are not available or are deemed unsuitable.
 - Anticoagulant therapy and malignancy: Overall, NOACs 
may appear as a valid option in patients with AF and 
malignancy based on the few available data from RCTs 
as well as using extrapolations from cancer-related VTE 
treatment. Antithrombotic therapy in patients with AF 
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suffering from a malignancy needs a dedicated interdisci-
plinary team approach. Especially when myelosuppressive 
chemotherapy or radiation therapy is planned, temporary 
dose reduction or cessation of NOAC therapy needs to be 
evaluated, taking into account full blood counts including 
platelets, renal/liver function, and physical signs of bleed-
ing. Gastric protection with PPI or H2 blockers should be 
considered in all such patients. 
 - Post kidney transplantation - there are no data on the 
use of NOACs in AF patients. Jan Steffel et al. Europace 
2021; 00:1–65. doi:10.1093/europace/euab065.
PREVENTIVE CARDIOLOGY 
Participation in exercise-based cardiac  
rehabilitation is related to reduced total  
mortality in both men and women post  
myocardial infarction: results from  
the SWEDEHEART registry
Although, meta-analyses consistently report that participa-
tion in exercise-based cardiac rehabilitation (exCR) reduces the 
cardiovascular mortality, there are conflicting results regarding 
effects on total mortality. Presently, many eligible patients do 
not receive exCR in clinical practice. This is a longitudinal, 
observational cohort study including 20.895 patients from the 
SWEDEHEART registry with a mean follow-up of 4.5 years. 
Mortality data were obtained from the Swedish National Popu-
lation Registry. Using Cox regression for proportional odds and 
taking a wide range of potential confounders into consideration, 
participation in exCR was related to significantly lower total 
mortality [hazard ratio (HR) 0.72, 95% confidence interval 
0.62–0.83]. Exercise-based CR participation was related to 
lowered total mortality in most of the investigated subgroups. 
The risk reduction was more pronounced in women than in 
men (HR 0.54 vs. 0.81, respectively). The above-mentioned 
results support the recommendations to participate in exCR, 
and hence we argue that exCR should be a mandatory part of 
comprehensive CR programs, offered to all patients post-MI. 
Örjan Ekblom, et al. European Journal of Preventive Cardiol-
ogy, https://doi.org/10.1093/eurjpc/zwab083.
CARDIAC ARREST and CARDIOPULMONARY 
RESUSCITATION
European Resuscitation Council Guidelines 2021: 
Cardiac arrest in special circumstance
The European Resuscitation Council (ERC) Cardiac Arrest 
in Special Circumstances guidelines based on the 2020 Inter-
national Consensus on Cardiopulmonary Resuscitation Science 
with Treatment Recommendations. This section provides 
guidelines on the modifications required to basic and advanced 
life support for the prevention and treatment of cardiac arrest 
in special circumstances; specifically special causes (hypoxia, 
trauma, anaphylaxis, sepsis, hypo/hyperkalemia and other 
electrolyte disorders, hypothermia, avalanche, hyperthermia 
and malignant hyperthermia, pulmonary embolism, coronary 
thrombosis, cardiac tamponade, tension pneumothorax, toxic 
agents), special settings (operating room, cardiac surgery, 
catheter laboratory, dialysis unit, dental clinics, transporta-
tion (in-flight, cruise ships), sport, drowning, mass casualty 
incidents), and special patient groups (asthma and COPD, 
neurological disease, obesity, pregnancy). Carsten Lott, et al. 
Resuscitation. 2021;161:152–219. doi: 10.1016/j.resuscita-
tion.2021.02.011.
